where to buy aod9604 AOD-9604 | Lumera Labs

Patients who are primarily seeking metabolic and mitochondrial support rather than isolated fat loss may find MOTS-c's broader mechanism more aligned with their goals

Activating sirtuins through adequate NAD+ levels is associated with improved mitochondrial function, reduced inflammation, and extended cellular lifespan

As a small-molecule inhibitor targeting specific enzymatic activity, it has gained significant attention for its potential influence on adipocyte function, metabolic efficiency, and body-composition dynamics

Based on the clinical evidence and the patient profiles where the compound appears most applicable, the following characteristics tend to describe good candidates for AOD 9604 evaluation when it is medically supervised: Patients with stubborn localized fat deposits that have not responded to diet and exercise, particularly visceral and lower abdominal fat Patients who cannot tolerate GLP-1 medications due to nausea, gastrointestinal side effects, or contraindications Active patients with reasonable baseline metabolic health who want a targeted lipolytic tool to complement their training and nutrition program Patients already on a peptide protocol who want to add a fat-targeting element to a GHK-Cu, NAD+, or sermorelin stack Patients who are not candidates for stimulant-based fat loss medications due to cardiovascular sensitivity, anxiety, or blood pressure concerns AOD 9604 is not appropriate as a standalone weight loss strategy for patients with significant obesity, insulin resistance, or metabolic syndrome

A reasonable titration schedule might look like this: Week 1: 200mcg once daily Week 2: 300mcg once daily Week 3 onward: 300-500mcg based on response and tolerance Optimizing injection technique Poor injection technique contributes to injection site reactions and potentially to other effects like nausea from anxiety around the process